A Nuclear Function of β-Arrestin1 in GPCR Signaling: Regulation of Histone Acetylation and Gene Transcription

Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, The Graduate School, Chinese Academy of Sciences, Shanghai 200031, China.
Cell (Impact Factor: 32.24). 02/2006; 123(5):833-47. DOI: 10.1016/j.cell.2005.09.011
Source: PubMed


Chromatin modification is considered to be a fundamental mechanism of regulating gene expression to generate coordinated responses to environmental changes, however, whether it could be directly regulated by signals mediated by G protein-coupled receptors (GPCRs), the largest surface receptor family, is not known. Here, we show that stimulation of delta-opioid receptor, a member of the GPCR family, induces nuclear translocation of beta-arrestin 1 (betaarr1), which was previously known as a cytosolic regulator and scaffold of GPCR signaling. In response to receptor activation, betaarr1 translocates to the nucleus and is selectively enriched at specific promoters such as that of p27 and c-fos, where it facilitates the recruitment of histone acetyltransferase p300, resulting in enhanced local histone H4 acetylation and transcription of these genes. Our results reveal a novel function of betaarr1 as a cytoplasm-nucleus messenger in GPCR signaling and elucidate an epigenetic mechanism for direct GPCR signaling from cell membrane to the nucleus through signal-dependent histone modification.

Download full-text


Available from: Rongxi Yang,
    • "This enables CREB to bind to the CRE sequences present in promoter regions and to consequently initiate transcription of the target gene [3]. Alternatively, transcription might be achieved through b-arrestinmediated signaling [4] [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We here present an improved and simplified assay to study signal transduction of the Gs-class of G-coupled protein-coupled receptors (GPCRs). The assay is based on a single plasmid combining the genes for any Gs protein-coupled GPCR and the cAMP response element-related expression of enhanced yellow fluorescent protein. Upon transfection, stable human embryonic kidney 293 cells (HEK293 cell lines presented high assay sensitivity and an unprecedented signal-to-noise ratio of up to 300, even in the absence of Tricostatin A. The robustness of the assay was demonstrated through the cloning of reporter gene cell lines with melanocortin 4 receptor (MC4R), the human type I pituitary adenylate cyclase activating polypeptide receptor (hPAC1), and the two vasoactive intestinal peptide receptors,VPAC1 and VPAC2.
    Analytical Biochemistry 02/2015; 476. DOI:10.1016/j.ab.2015.02.003 · 2.22 Impact Factor
  • Source
    • "Recently, although b-arrestin2 was reported to participate in the initiation and progression of myeloid leukaemia (Fereshteh et al, 2012), the critical role of b-arrestin1 in human haematological malignancies remains unresolved. More interestingly, b-arrestin1 has the ability of nuclear translocation and histone H4 acetylation modification with the delta-opioid receptors activated (Kang et al, 2005). The acetylation status of histone H4 terminal tails is one component of chromatin remodelling and chromatin-based processes including gene expression (Brower-Toland et al, 2005). "
    R Qin · K Li · X Qi · X Zhou · L Wang · P Zhang · L Zou ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: β-Arrestins are scaffold proteins that interact with various cellular signals. Although β-arrestin2 mediates the initiation and progression of myeloid leukaemia, the critical role of β-arrestin1 in the chronic myeloid leukaemia (CML) is still unknown. The aim of this study is to investigate the essential function of β-arrestin1 in CML. Methods: The expressions of β-arrestin1 and BCR/ABL in CML patients, animal models and K562 cells were measured by RT–PCR, immunofluorescence and western blotting. The effect of β-arrestin1 on CML animal models and K562 cells by colony formation, MTT and survival analysis were assessed. BCR/ABL H4 acetylation was analysed through the use of Chromatin-immunoprecipitation (ChIP) -on-chip and confirmed by ChIP respectively. Co-immunoprecipitation and confocal were examined for the binding of β-arrestin1 with enhancer of zeste homologue 2 (EZH2). Results: The higher expression of β-arrestin1 is positively correlated with clinical phases of CML patients. Depletion of β-arrestin1 decelerates progression of K562 and primary cells, and increases survival of CML mice. Importantly, silenced β-arrestin1 results in the decrease of BCR/ABL H4 acetylation level in K562 cells. Further data illustrate that nuclear β-arrestin1 binds to EZH2 to mediate BCR/ABL acetylation and thus regulates cell progression in K562 cells and the survival of CML mice. Conclusions: Our findings reveal a novel function of β-arrestin1 binding to EZH2 to promote CML progression by regulating BCR/ABL H4 acetylation.
    British Journal of Cancer 06/2014; 111(3). DOI:10.1038/bjc.2014.335 · 4.84 Impact Factor
  • Source
    • "). Thus, sites shared by ARRB1 and p300 have a greater affinity for promoter regions, consistent with previous reports of a ARRB1/p300 physical interaction within transcriptional complexes at promoter regions (Kang et al, 2005; Dasgupta et al, 2011). In addition, ARRB1 was found to be tightly centred on TSS and RNA PolII (RNAPII), which typically binds proximal promoter regions of actively transcribed genes, further emphasising ARRB1's affinity for proximal functional regions and suggesting a major role for this protein in gene expression regulation (Fig 3D and E). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumour cells sustain their high proliferation rate through metabolic reprogramming, whereby cellular metabolism shifts from oxidative phosphorylation to aerobic glycolysis, even under normal oxygen levels. Hypoxia-inducible factor 1A (HIF1A) is a major regulator of this process, but its activation under normoxic conditions, termed pseudohypoxia, is not well documented. Here, using an integrative approach combining the first genome-wide mapping of chromatin binding for an endocytic adaptor, ARRB1, both in vitro and in vivo with gene expression profiling, we demonstrate that nuclear ARRB1 contributes to this metabolic shift in prostate cancer cells via regulation of HIF1A transcriptional activity under normoxic conditions through regulation of succinate dehydrogenase A (SDHA) and fumarate hydratase (FH) expression. ARRB1-induced pseudohypoxia may facilitate adaptation of cancer cells to growth in the harsh conditions that are frequently encountered within solid tumours. Our study is the first example of an endocytic adaptor protein regulating metabolic pathways. It implicates ARRB1 as a potential tumour promoter in prostate cancer and highlights the importance of metabolic alterations in prostate cancer.
    The EMBO Journal 05/2014; 33(12). DOI:10.15252/embj.201386874 · 10.43 Impact Factor
Show more